MULTIPLE MYELOMA

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses recent advancements in the treatment paradigm for multiple myeloma.

Treatment with chimeric antigen receptor (CAR) T cells that target B-cell maturation protein (BMCA) achieved clinical remissions in 33 out of 35 patients (94%) with relapsed or refractory multiple myeloma in early results from a Chinese study presented at the 2017 ASCO Annual Meeting.

NYU Langone’s Perlmutter Cancer Center (PCC) has announced that Ahmad Samer Al-Homsi, MD, MBA, will lead a new bone marrow transplantation program at the center for treating blood-borne cancers, including leukemia, lymphoma, and multiple myeloma.

An overview of FDA news that happened in April.

Daratumumab has been approved by the European Commission for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma following at least 1 prior therapy.

Consolidation therapy with lenalidomide, bortezomib, and dexamethasone (RVD) extended progression-free survival in patients with multiple myeloma when used in conjunction with stem cell transplantation compared with RVD alone

John A. Snowden, MD, discusses guidelines that offer recommendations for screening and management of myeloma.

FDA approval is being sought for the use of denosumab for the prevention of skeletal-related events in patients with multiple myeloma, according to Amgen, the developer of the RANK ligand inhibitor.

An investigational anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy demonstrated an objective response rate of 78% in patients with relapsed/refractory multiple myeloma.

Clinical trials of selinexor, which is being explored in several tumor types, have been placed on clinical hold by the FDA.

Lenalidomide has been approved by the FDA as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant.

Multiple myeloma expert Kenneth C. Anderson, MD, will serve as president of the American Society of Hematology through the end of this year.

Based on data from 2 phase III trials, the EMA’s CHMP has recommended approval of lenalidomide as a maintenance therapy following autologous stem cell transplant for patients with newly diagnosed multiple myeloma.

Saad Z. Usmani, MD, discusses the POLLUX update and PAVO findings presented at ASH, as well as the latest developments with daratumumab.

Monoclonal Antibodies in Relapsed Multiple Myeloma with Ola Landgren, MD, PhD

Monoclonal Antibodies in Relapsed Multiple Myeloma with Ola Landgren, MD, PhD

Monoclonal Antibodies in Relapsed Multiple Myeloma with Cristina Gasparetto, MD

Monoclonal Antibodies in Relapsed Multiple Myeloma with Cristina Gasparetto, MD

Kevin R. Kelly, MD, PhD, discusses the differences seen between ethnic groups in multiple myeloma diagnosis and response to treatment.

Cristina Gasparetto, MD, discuss treatment considerations and options for patients with multiple myeloma based on 2 case scenarios.

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses results of a study that determined lenalidomide (Revlimid) is a highly-effective maintenance therapy in myeloma patients of all ages.